

Date: 6th November, 2025

To,

The Manager,

Department of Corporate Services,

BSE Limited

P. J. Towers, Dalal Street,

Fort, Mumbai – 400 001

Scrip Code:533573

To,

The Manager,

Listing Department,

National Stock Exchange of India Ltd.

'Exchange Plaza', Bandra Kurla Complex,

Bandra (E), Mumbai – 400 051

NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned matter, we wish to inform you that the Company's Branch office has been converted into a Wholly Owned Subsidiary (WOS) of the Company with the name Alembic Pharmaceuticals Scientific Office L.L.C.

The disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as Annexure – I.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Manisha Saraf Company Secretary

Encl: A/a



Annexure-I

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as specified in Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Sr.	Particulars	
No.	i aiticulais	
i)	Name of the target entity, details in brief such as size, turnover etc	Alembic Pharmaceuticals Scientific Office L.L.C. is a company incorporated in the United Arab Emirates.
ii)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	Alembic Pharmaceuticals Scientific Office L.L.C. is a wholly owned subsidiary of the Company and does not fall under related party transaction. The promoter / promoter/
		promoter group are not
		interested in the transaction.
iii)	Industry to which the entity being acquired belongs	Pharmaceuticals
iv)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable
v)	Brief details of any governmental or regulatory approvals required for the acquisition	Dep. of Economic Development, Government of Dubai, has issued the licence.
vi)	Indicative time period for completion of the acquisition	NA
vii)	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash



viii)	Cost of acquisition and/or the price at which the shares are acquired;	AED 50,000 (Arab Emirates Dirhams Fifty Thousand)
ix)	Percentage of shareholding / control acquired and / or number of shares acquired	100%.
x)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Not applicable, as this intimation is about a newly incorporated entity.